Affordable Access

Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis.

Authors
  • Ulrich-Vinther, Michael1
  • Carmody, Emily E
  • Goater, J Jeffrey
  • S balle, Kjeld
  • O'Keefe, Regis J
  • Schwarz, Edward M
  • 1 Department of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY 14642, USA.
Type
Published Article
Journal
The Journal of bone and joint surgery. American volume
Publication Date
August 2002
Volume
84-A
Issue
8
Pages
1405–1412
Identifiers
PMID: 12177271
Source
Medline
License
Unknown

Abstract

Currently, there is no approved drug therapy to prevent or inhibit periprosthetic osteolysis. Although preclinical studies have identified potential drug therapies (i.e., bisphosphonates), there is no evidence that these drugs can effectively treat aseptic loosening in patients. This is the first evidence that in vivo OPG gene therapy can be used to prevent wear debris-induced osteolysis.

Report this publication

Statistics

Seen <100 times